What is the fair value of Resverlogix Corp (OTC-RVXC.F) stock?

The current fair value estimate for Resverlogix Corp (OTC-RVXC.F) is $0.059. This implies an estimated downside of 7.1% versus the current market price.

Is Resverlogix Corp (OTC-RVXC.F) undervalued or overvalued?

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 7.1% versus the current market price.

How is the financial health of Resverlogix Corp?

The current financial health read for Resverlogix Corp (OTC-RVXC.F) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Resverlogix Corp's next earnings date?

The next earnings date currently listed for Resverlogix Corp (OTC-RVXC.F) is October 6, 2026.

Does Resverlogix Corp (OTC-RVXC.F) pay dividends?

The latest available data indicates no current dividend yield for Resverlogix Corp (OTC-RVXC.F).

What is the market capitalization of Resverlogix Corp?

The current market capitalization listed for Resverlogix Corp is 20.805 M.

What is the enterprise value of Resverlogix Corp?

The current enterprise value listed for Resverlogix Corp is 114.5 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Resverlogix Corp?

The ticker symbol for Resverlogix Corp is OTC-RVXC.F, and the stock is listed on OTC Markets.

Where is Resverlogix Corp (OTC-RVXC.F) listed?

Resverlogix Corp (OTC-RVXC.F) is listed on OTC Markets.

What is the debt-to-total-capital ratio for Resverlogix Corp?

The current debt-to-total-capital ratio listed for Resverlogix Corp is 80.5%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Resverlogix Corp?

The free float listed for Resverlogix Corp is 73.0%. Free float helps investors understand how much of the share base is available for public trading.

Resverlogix Corp (RVXCF) Fair Value & Stock Analysis

Resverlogix Corp (RVXCF)

Resverlogix Corp. is a late-stage clinical biotechnology company focused on developing therapeutics for chronic illnesses. Its lead candidate is apabetalone (RVX-208), a small-molecule BET inhibitor being studied for use in conditions including cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low HDL cholesterol, recent acute coronary syndrome, and post-COVID-19 conditions. The company has collaboration arrangements with Eversana Life Science Services, LLC to support potential commercialization of apabetalone for COVID-19 in the United States and Canada, as well as development efforts in cardiovascular and pulmonary arterial hypertension indications, and with Medison Pharma Ltd. Resverlogix is headquartered in Calgary, Canada, and its common stock is listed on OTC Markets.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Overall Financial Health	Dividend Yield	Next Earnings Date	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
OTC-RVXC.F	$0.059	-7.1% Downside	Fair	Not available	Not available	Weak	0.0%	October 6, 2026	20.805 M	114.5 M	80.5%	73.0%	-343.4	35.4%